+

WO1996002641A3 - Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of synovial sarcoma - Google Patents

Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of synovial sarcoma Download PDF

Info

Publication number
WO1996002641A3
WO1996002641A3 PCT/GB1995/001704 GB9501704W WO9602641A3 WO 1996002641 A3 WO1996002641 A3 WO 1996002641A3 GB 9501704 W GB9501704 W GB 9501704W WO 9602641 A3 WO9602641 A3 WO 9602641A3
Authority
WO
WIPO (PCT)
Prior art keywords
synovial sarcoma
prophylactic
diagnosis
materials
therapeutic treatment
Prior art date
Application number
PCT/GB1995/001704
Other languages
French (fr)
Other versions
WO1996002641A2 (en
Inventor
Colin Stephen Cooper
Barry Austin Gusterson
Original Assignee
Cancer Res Campaign Tech
Colin Stephen Cooper
Barry Austin Gusterson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Campaign Tech, Colin Stephen Cooper, Barry Austin Gusterson filed Critical Cancer Res Campaign Tech
Priority to AU29865/95A priority Critical patent/AU2986595A/en
Priority to EP95925919A priority patent/EP0769053A2/en
Publication of WO1996002641A2 publication Critical patent/WO1996002641A2/en
Publication of WO1996002641A3 publication Critical patent/WO1996002641A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a method for diagnosing the presence or absence of synovial sarcoma which comprises obtaining a sample derived from a tissue of a subject; contacting the sample with a specific binding member (sbm) which is specific for a binding partner (bp) which is characteristic of synovial sarcoma such that the presence of bp in the sample is diagnostic of synovial sarcoma, the bp being absent from an equivalent sample derived from a subject without synovial sarcoma; and detecting any binding of the sbm to its bp. Binding partners characteristic of synovial sarcoma are SSX and SYT sequences and fusion sequences thereof. Sequences, reagents and therapeutic methods and pharmaceuticals are also provided.
PCT/GB1995/001704 1994-07-19 1995-07-19 Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of synovial sarcoma WO1996002641A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU29865/95A AU2986595A (en) 1994-07-19 1995-07-19 Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of synovial sarcoma
EP95925919A EP0769053A2 (en) 1994-07-19 1995-07-19 Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of synovial sarcoma

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9414580.2 1994-07-19
GB9414580A GB9414580D0 (en) 1994-07-19 1994-07-19 Materials and methods relating to the diagnosis of synovial sarcomas

Publications (2)

Publication Number Publication Date
WO1996002641A2 WO1996002641A2 (en) 1996-02-01
WO1996002641A3 true WO1996002641A3 (en) 1996-03-07

Family

ID=10758576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/001704 WO1996002641A2 (en) 1994-07-19 1995-07-19 Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of synovial sarcoma

Country Status (5)

Country Link
EP (1) EP0769053A2 (en)
AU (1) AU2986595A (en)
CA (1) CA2195531A1 (en)
GB (1) GB9414580D0 (en)
WO (1) WO1996002641A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291658B1 (en) 1997-05-05 2001-09-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding SSX family members and thereof
US6287756B1 (en) * 1997-05-05 2001-09-11 Ludwig Institute For Cancer Research Methods for determining presence of cancer in a sample by determining expression of an SSX gene
US6548064B1 (en) * 1997-05-05 2003-04-15 Ludwig Institute For Cancer Research Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA molecules
US6800730B1 (en) * 1998-10-02 2004-10-05 Ludwig Institute For Cancer Research Isolated peptides which bind to MHC class II molecules, and uses thereof
WO2004020668A2 (en) * 2002-08-30 2004-03-11 Oncotherapy Science, Inc. Method for treating synovial sarcoma
US7803370B2 (en) 2002-08-30 2010-09-28 Oncotherapy Science, Inc. Method for treating synovial sarcoma
ES2381841T3 (en) * 2003-07-11 2012-06-01 Oncotherapy Science, Inc. Method to treat synovial sarcoma
WO2005010190A1 (en) * 2003-07-22 2005-02-03 Ludwig Institute For Cancer Research Ssx-2 peptides presented by hla class ii molucules
RU2412203C2 (en) 2006-06-21 2011-02-20 Онкотерапи Сайенс, Инк. Tumour-targeted monoclonal antibodies against fzd10 and their application
US20110061116A1 (en) * 2007-07-31 2011-03-10 University Of Utah Research Foundation Animal Model of Synovial Sarcoma
WO2009096112A1 (en) 2008-01-31 2009-08-06 Osaka University Tag peptide and use thereof
TWI762516B (en) 2016-10-06 2022-05-01 日商腫瘤療法 科學股份有限公司 Monoclonal antibodies against FZD10 and their uses
CN110660451B (en) * 2018-06-13 2023-04-28 广州华大基因医学检验所有限公司 Method, device and application for determining whether fusion genes exist in biological sample

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084566A (en) * 1987-05-04 1992-01-28 Michael Litt DNA probe which reveals a hypervariable region on human chromosone 1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084566A (en) * 1987-05-04 1992-01-28 Michael Litt DNA probe which reveals a hypervariable region on human chromosone 1

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
A.J. CREW ET AL.: "Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated boc in human synovial sarcoma", EMBO J., vol. 14, no. 10, 15 May 1995 (1995-05-15), OXFORD UNIVERSITY PRESS,GB;, pages 2333 - 2340 *
B. DE LEEUW ET AL.: "Identification of a yeast artificial chromosome (YAC) spanning the synovial sarcoma-specific t(X;18)(11.2;q11.2) breakpoint", GENES, CHROMOSOMES & CANCER, vol. 6, no. 3, WILEY-LISS, INC.; NEW YORK, US, pages 182 - 189 *
B. DE LEEUW ET AL.: "Identification of two alternative fusion genes, SYT-SSX1 and SYT-SSX2, in t(X;18)(p11.2;q11.2)-positive synovial sarcomas", HUMAN MOLECULAR GENETICS, vol. 4, no. 6, OXFORD UNIVERSITY PRESS, UK, pages 1097 - 1099 *
B. DE LEEUW ET AL.: "Molecular cloning of the synovial sarcoma-specific translocation (X;18)(p11.2;q11.2) breakpoint", HUMAN MOLECULAR GENETICS, vol. 3, no. 5, OXFORD UNIVERSITY PRESS, UK, pages 745 - 749 *
B. DE LEEUW ET AL.: "Sublocalization of the synovial sarcoma-associated t(X;18) chromosomal breakpoint in Xp11.2 using cosmid cloning and fluorescence in situ hybridization", ONCOGENE, vol. 8, no. 6, MACMILLAN PRESS LTD.,LONDON,UK, pages 1457 - 1463 *
B.R. REEVES ET AL.: "Characterization of the translocation between chromosomes X and 18 in human synovial sarcomas", ONCOGENE, vol. 4, no. 3, MACMILLAN PRESS LTD.,LONDON,UK, pages 373 - 378 *
C. COOPER ET AL.: "Characterization of novel genes SYT and SSX involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma", J. CELL. BIOCHEM. SUPPL. 0 (19A),, WILEY LISS, NEW YORK, US, pages 50 *
D. OLDE WEGHUIS ET AL.: "A synovial sarcoma with a complex t(X;18;5;4) and a break in the ornithine aminotransferase (OAT)L1 cluster on Xp11.2", GENES, CHROMOSOMES & CANCER, vol. 9, no. 4, WILEY-LISS, INC.; NEW YORK, US, pages 288 - 291 *
DE LEEUW, B. ET AL: "Distinct Xp11.2 breakpoint regions in synovial sarcoma revealed by metaphase and interphase FISH: relationship to histologic subtypes", CANCER GENET. CYTOGENET. (1994), 73(2), 89-94 CODEN: CGCYDF;ISSN: 0165-4608 *
J. CLARK ET AL.: "Identification of novel genes, SYT and SSX, involved in the (tX;18)(p11.2;q11.2) translocation found in human synovial sarcoma", NATURE GENETICS, vol. 7, no. 4, NATURE PUBLISHING CO., NEW YORK, US, pages 502 - 508 *
J.C. KNIGHT ET AL.: "Localization of the synovial sarcoma t(X;18)(p11.2) breakpoint by flourescence in situ hybridization", HUMAN MOLECULAR GENETICS, vol. 1, no. 8, OXFORD UNIVERSITY PRESS, UK, pages 633 - 637 *
J.M. SHIPLEY ET AL.: "The t(X;18)(p11.2;q11.2) translocation found in human synovial sarcomas involves two distinct loci on the X chromosome", ONCOGENE, vol. 9, no. 5, MACMILLAN PRESS LTD.,LONDON,UK, pages 1447 - 1453 *
M. LITT AND N.E. BUROKER: "DNA probe p1-p79 consensus sequence", EMBL-SEQUENCE DATABASE, 22 May 1992 (1992-05-22), HEIDELBERG, BRD; *

Also Published As

Publication number Publication date
EP0769053A2 (en) 1997-04-23
WO1996002641A2 (en) 1996-02-01
GB9414580D0 (en) 1994-09-07
CA2195531A1 (en) 1996-02-01
AU2986595A (en) 1996-02-16

Similar Documents

Publication Publication Date Title
WO1996002641A3 (en) Materials and methods relating to the diagnosis and prophylactic and therapeutic treatment of synovial sarcoma
WO1998053076A3 (en) Compounds for diagnosis of tuberculosis and methods for their use
WO1998016645A3 (en) Compounds and methods for diagnosis of tuberculosis
MX9801687A (en) Compounds and methods for diagnosis of tuberculosis.
AU4756896A (en) Test apparatus, system and method for the detection of test samples
EP1318399A3 (en) Passive sample detection to initiate timing of an assay
DE59708311D1 (en) Volume-independent diagnostic test carrier and method for the determination of analytes with its help
EP2284536A3 (en) Multi-array, multi-specific electrochemiluminescence testing
EP0987550A3 (en) Analytical test device and method of use
EP0890840A3 (en) Assaying for collagen degradation in vivo
WO2003008972A3 (en) Method for simultaneous multiple probes/multiple targets screening procedure
WO2001062893A3 (en) Compounds and methods for diagnosis and immunotherapy of tuberculosis
DE69535273D1 (en) DETECTION DEVICE AND METHOD
AU692651B2 (en) Test set for analysis of body fluids, process for producing it and analytical procedure
AU7260496A (en) A method and diagnostic test kit for use in aiding the diagnosis of fibromyyalgia and chronic fatigue syndrome (CFS)
AU2667197A (en) Stabilized preparations of human troponins and modifications thereof, diagnostic assay methods and assay kits
AU2514195A (en) Method of rapid analyte detection
CA2234416A1 (en) Immunochemical determination of multivalent analytes
WO1999024611A3 (en) Analyte detection process using dual labeled probes
EP1652918A3 (en) Methods for detecting protein interactions using conformationally constrained peptides
HK1021229A1 (en) A in vitro method of determining the presence of aprotein in an isolated biological sample.
ES2163009T3 (en) PROCEDURE FOR THE DOMESTIC POWDER ANALYSIS.
CA2101166A1 (en) Method for detection of anti-rna-antibodies
EP0387027A3 (en) Endometriosis diagnosis methods and reagents
AU3140497A (en) Methods and kits for the detection of endotoxin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2195531

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1995925919

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 289893

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1995925919

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995925919

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载